Press Releases

Filter per year
June 21, 2024
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
June 21, 2024
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
June 20, 2024
Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
June 3, 2024
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
June 1, 2024
Media Update: Sanofi update on Zantac litigation
May 31, 2024
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
May 31, 2024
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
May 31, 2024
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
May 30, 2024
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
May 27, 2024
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
May 22, 2024
Media Update: New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma
May 21, 2024
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
May 20, 2024
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
May 13, 2024
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty
May 10, 2024
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
May 2, 2024
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
April 30, 2024
Press Release: Annual General Meeting of April 30, 2024
April 26, 2024
Media Update: New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases
April 25, 2024
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
April 23, 2024
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Press Statements